The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either "atypical" myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow-derived genomic DNA from 245 patients--119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophilic leukemia (CNL)--was screened for the JAK2 V617F mutation. A mutant allele was detected in 11 patients: 3 with CMML (3%), 5 with MDS (5%), 2 with SM, and 1 with CNL. Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML. The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders.

[1]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[2]  A. Tefferi.  The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. , 1998, Mayo Clinic proceedings.

[3]  Duardo,et al.  RESPONSE TO IMATINIB MESYLATE IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES WITH REARRANGEMENTS OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA , 2002 .

[4]  E. Baxter,et al.  Imatinib for systemic mast-cell disease , 2003, The Lancet.

[5]  M. Beran,et al.  Chronic myelomonocytic leukemia: myeloproliferative variant. , 2004, Current hematology reports.

[6]  D. Higgs,et al.  Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. , 2005, Blood.

[7]  J. Bueno,et al.  Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. , 2002, Leukemia research.

[8]  C. Sawyers,et al.  Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. , 2004 .

[9]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[10]  J. Boultwood,et al.  Clonality in the Myelodysplastic Syndromes , 2001, International journal of hematology.

[11]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[12]  A. Tefferi,et al.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. , 2004, Blood.

[13]  Tiffany A. Wallace,et al.  A True Jak of All Trades , 2004 .

[14]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Tefferi,et al.  WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature , 2005, Leukemia.

[16]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  B. Druker,et al.  AMN107: tightening the grip of imatinib. , 2005, Cancer cell.

[18]  U. Germing,et al.  Problems in the classification of CMML--dysplastic versus proliferative type. , 1998, Leukemia research.

[19]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[20]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[21]  J. Cortes.  CMML: a biologically distinct myeloproliferative disease. , 2003, Current hematology reports.

[22]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[23]  M. Pfeilstöcker,et al.  Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution. , 2001, Leukemia research.

[24]  B. Durie.  The epidemiology of multiple myeloma. , 2001, Seminars in hematology.

[25]  A. Tefferi.  Chronic myeloid disorders: Classification and treatment overview. , 2001, Seminars in hematology.

[26]  D. Steensma,et al.  The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. , 2003, Leukemia research.